Redeye strengthens its positive view of Proact following a solid Q3 report in basically every aspect. System revenue was strong partly thanks to a catch-up effect, but the outlook remains solid. Recurring revenue continued to show robust organic growth, and the high TCV suggests the trend will persist. We raise our forecasts and Base Case slightly.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking.